The 36-month beta value for ELYM is also noteworthy at -0.34. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for ELYM is 51.90M, and at present, short sellers hold a 2.18% of that float. The average trading volume of ELYM on September 25, 2024 was 343.31K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ELYM) stock’s latest price update
Eliem Therapeutics Inc (NASDAQ: ELYM) has seen a decline in its stock price by -14.02 in relation to its previous close of 7.63. However, the company has experienced a -17.59% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-11 that SEATTLE and CAMBRIDGE, United Kingdom, Sept. 11, 2024 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today members of the management team will participate at the Stifel 2024 Virtual Immunology and Inflammation Summit being held September 17-18, 2024.
ELYM’s Market Performance
Eliem Therapeutics Inc (ELYM) has experienced a -17.59% fall in stock performance for the past week, with a 9.33% rise in the past month, and a -8.51% drop in the past quarter. The volatility ratio for the week is 10.28%, and the volatility levels for the past 30 days are at 8.84% for ELYM. The simple moving average for the last 20 days is -12.59% for ELYM stock, with a simple moving average of 24.10% for the last 200 days.
ELYM Trading at -9.76% from the 50-Day Moving Average
After a stumble in the market that brought ELYM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.20% of loss for the given period.
Volatility was left at 8.84%, however, over the last 30 days, the volatility rate increased by 10.28%, as shares surge +10.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.15% lower at present.
During the last 5 trading sessions, ELYM fell by -17.59%, which changed the moving average for the period of 200-days by +151.34% in comparison to the 20-day moving average, which settled at $7.54. In addition, Eliem Therapeutics Inc saw 142.96% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ELYM starting from Pimblett Emily, who sale 1,191 shares at the price of $8.18 back on Sep 20 ’24. After this action, Pimblett Emily now owns 7,564 shares of Eliem Therapeutics Inc, valued at $9,741 using the latest closing price.
Morisset Valerie, the EVP, R&D AND CSO of Eliem Therapeutics Inc, sale 69,005 shares at $8.03 during a trade that took place back on Jul 22 ’24, which means that Morisset Valerie is holding 31,317 shares at $554,170 based on the most recent closing price.
Stock Fundamentals for ELYM
The total capital return value is set at -0.08. Equity return is now at value -38.35, with -37.51 for asset returns.
Based on Eliem Therapeutics Inc (ELYM), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at 0.57. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -15.54.
Currently, EBITDA for the company is -40.27 million with net debt to EBITDA at 12.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 60.41.
Conclusion
In summary, Eliem Therapeutics Inc (ELYM) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
